Several studies have suggested that endothelial cells participate in tumor development. Soluble E-selectin (sE-selectin) is specifically released by activated endothelial cells, and its serum concentration can be considered a marker of endothelial activation. In this study, we assessed the prognostic value of sE-selectin concentrations in node-negative breast cancer patients. Serum sE-selectin concentrations were measured by an ELISA method prior to surgery in 456 node-negative breast cancer patients. We analyzed also tumor size (TS), histoprognostic grading, and steroid hormone receptor status. The mean sE-selectin concentration was 24.9 +/- 15.0 ng/ml. The sE-selectin concentrations were mildly correlated with the TS but not with the other factors. For prognostic analyses, the median follow-up duration was 7.5 years. The cutoff sE-selectin concentration used was 40 ng/ml. In overall survival studies, univariate analyses demonstrated a prognostic value of sE-selectin, TS, and histoprognostic grading, and multivariate analyses demonstrated a prognostic value of sE-selectin and TS. For disease-free survival, univariate and multivariate analyses demonstrated a prognostic value of sE-selectin and TS. sE-selectin concentration is an easily measurable and strong prognostic factor in node-negative breast cancer patients. These results provide further evidence for the role of adhesion molecules expression by endothelial cells in tumor progression.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Performance of sentinel lymph node biopsy after neoadjuvant chemotherapy in clinically node positive breast cancer patients: systematic review and meta-analysis.
Int J Surg
January 2025
Department of Surgery, American University of Beirut, Beirut, Lebanon.
Background: The reliability of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in patients with initially node-positive breast cancer is still controversial. This meta-analysis is conducted to investigate the feasibility and accuracy of SLNB after NACT in patients with initially positive axillary nodes.
Methods: We conducted a literature search using Medline, PubMed, Embase, Central, and SCOPUS up until April 2021 for studies on the performance of SLNB following NACT.
Comparative survival outcomes of neoadjuvant and adjuvant therapy in patients with T1c, node-negative, triple-negative breast cancer: A population-based analysis.
Breast
January 2025
Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address:
Background: Ongoing discussions persist concerning the precedence of neoadjuvant therapy (NAT) relative to adjuvant therapy (AT) for patients with T1c, node-negative, triple-negative breast cancer (TNBC), and pertinent guidelines for these individuals are absent.
Methods: Women diagnosed with T1cN0M0-stage TNBC who received chemotherapy and surgery were selected from the Surveillance, Epidemiology and End Results database (2010-2020). To balance baseline characteristics and mitigate selection bias, propensity score matching (PSM) was used to create the NAT and AT cohorts.
Construction and validation of nomograms to predict central lymph node metastasis in clinical node-negative unilateral papillary thyroid carcinoma.
Sci Rep
January 2025
Department of Thyroid and Breast Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
The scope of neck lymph node dissection remains controversial for unilateral papillary thyroid carcinoma (UPTC) patients with no clinical evidence of lymph node metastasis (cN0). This study aims to build and validate a model for predicting central lymph node metastasis (CLNM) in UPTC patients through preoperative basic information and intraoperative rapid frozen pathology results. Retrospective analysis covered 1928 patients with PTC from the Wuhan Union Hospital database (2010-2020), randomly split into training and validation sets in a 7:3 ratio.
View Article and Find Full Text PDFThe role of F-FDG PET/CT in detecting synchronous regional and distant metastatic disease in patients with an in-breast tumour recurrence.
Eur J Surg Oncol
December 2024
Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Background: In line with the trend towards minimally invasive, patient-tailored treatment, a selected group of patients with an in-breast tumour recurrence (IBTR) is treated by repeat breast-conserving treatment (BCT). To select eligible patients for repeat BCT, a reliable pre-operative work-up is essential. This study reports on the role of F-FDG PET/CT in detecting synchronous regional and distant metastases in patients with IBTR.
View Article and Find Full Text PDFPrediction of axillary nodal burden using preoperative magnetic resonance imaging scoring in patients with clinically node-negative breast cancer: a retrospective cohort study.
Gland Surg
December 2024
Department of Radiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Axillary lymph node metastasis (ALNM) is a significant predictor of overall patient survival; thus, precise evaluation of ALNM is essential for staging breast cancer, informing multimodal treatment strategies, and ensuring optimal patient care. This study aimed to establish a magnetic resonance imaging (MRI) scoring system for predicting extensive axillary nodal metastasis in patients with clinically node-negative breast cancer derived from preoperative breast and axillary MRI.
Methods: This study included 226 patients with clinically node-negative breast cancer who underwent preoperative breast and axillary MRI between January 1, 2010 and December 31, 2020 at King Chulalongkorn Memorial Hospital.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!